Difference between revisions 607282036 and 607282201 on enwiki

'''Zerona''' is a low-level laser device developed by Erchonia Corp. for non-invasive body slimming of the waist, hips, and thighs. It has been shown to disrupt [[adipocyte]], or fat cell, membranes causing the release of stored [[lipids]] and fatty material, in turn, promoting adipocyte collapse. The device was first introduced to the market in 2008 as an [[off-label use]] device for slimming, but later was granted 510k market clearance{{jargon-inline|date=May2014}} by the [[F(contracted; show full)apies to promote insulin sensitivity and reduce the risk of diabetes.  The Zerona, based on histological evidence, has proven to reduce adipose tissue fat mass of the waist, hips, and thighs while preventing fat cell death. The formation of the transitory pore within the adipocyte membrane results in adipocyte cell collapse and its return to a lean state.  Reduced fat mass is associated with the synthesis of beneficial hormones like adiponectin which promotes insulin sensitivity within numerous tissues.

A
n 2010 article published in the ''American Journal of Cosmetic Surgery in 2010'' demonstrated a statistically significant reduction in both serum triglyceride and total cholesterol levels following a standard two-week, six treatment Zerona administration.<ref>{{cite journal |first1=Robert F. |last1=Jackson |first2=Greg C. |last2=Roche |first3=Kevin |last3=Wisler |year=2010 |title=Reduction in Cholesterol and Triglyceride Serum Levels Following Low-Level Laser Irradiation: A Noncontrolled, Nonrandomized Pilot Study |journal=The American Journal of Cosmetic Surgery |volume=27 |issue=4 |pages=177–84 |url=http://www.erchonia.com/files/uploads/1/file/Jackson_Reduction%20in%20Cholesterol%20and%20Triglyceride%20Serum%20Levels%20Following%203LT_AJCS_2010.pdf}}</ref>

== References ==
{{reflist|2}}

==External links==
* [http://www.erchonia.com/ Erchonia Corp., Official Website]

[[Category:Laser medicine]]
[[Category:Management of obesity]]